KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC
- PMID: 30467046
- DOI: 10.1016/j.jtho.2018.07.103
KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC
Similar articles
-
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6. Eur J Cancer. 2020. PMID: 32388065
-
The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.Cancer Lett. 2016 Mar 1;372(1):75-81. doi: 10.1016/j.canlet.2015.12.015. Epub 2015 Dec 23. Cancer Lett. 2016. PMID: 26723875
-
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15. Lung Cancer. 2016. PMID: 26711930
-
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9. Oncologist. 2017. PMID: 28487464 Free PMC article. Review.
-
Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.Expert Rev Anticancer Ther. 2019 Jan;19(1):11-17. doi: 10.1080/14737140.2019.1554440. Epub 2018 Dec 4. Expert Rev Anticancer Ther. 2019. PMID: 30513023 Review.
Cited by
-
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.Cell Rep Med. 2024 Aug 20;5(8):101663. doi: 10.1016/j.xcrm.2024.101663. Epub 2024 Aug 1. Cell Rep Med. 2024. PMID: 39094577 Free PMC article.
-
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164. Int J Mol Sci. 2022. PMID: 35456982 Free PMC article. Review.
-
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Int J Mol Sci. 2024 Dec 3;25(23):12972. doi: 10.3390/ijms252312972. Int J Mol Sci. 2024. PMID: 39684685 Free PMC article. Review.
-
The clinical benefit of molecular re-assessments in management of progressive lung cancer.Transl Lung Cancer Res. 2021 Mar;10(3):1582-1587. doi: 10.21037/tlcr-20-996. Transl Lung Cancer Res. 2021. PMID: 33889532 Free PMC article.
-
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):741-761. doi: 10.3779/j.issn.1009-3419.2020.101.45. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32957170 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous